Please assess the completion status of the following clinical trial:

Trial Title: A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Age 18 and \< 75 years at baseline visit.~2. Diagnosis of Idiopathic PAH, Heritable PAH (including Hereditary Hemorrhagic Telangiectasia), Associated PAH (including collagen vascular disorders, drug+toxin exposure, repaired congenital heart disease repaired \> 5 years, portopulmonary disease, and human immunodeficiency virus (HIV) infection not on protease inhibitor).~3. PAH treatment naïve including any prostacycline, endothelin receptor antagonist, or phosphodiesterase inhibitors within 12 months prior to enrollment.~4. Previous Right Heart Catheterization that documented:~   1. Mean PAP; 25 mmHg.~  2. Pulmonary capillary wedge pressure \< 15 mmHg.~  3. Pulmonary Vascular Resistance; 3.0 Wood units or 240 dynes/sec/cm5 5.6MW distances; 150 m and \< 450 meters.~6. WHO functional class II or III as judged by principal investigators.~Exclusion Criteria:~Exclusion criteria:~1. Group II - V pulmonary hypertension.~2. PAH with unrepaired congenital heart defect.~3. Current or prior PAH treatments within the last 6-12 months including experimental PAH therapies (including but not limited to tyrosine kinase inhibitors, rho-kinase inhibitors, phosphodiesterase inhibitors, prostacycline, or cGMP modulators).~4. TLC \< 60% predicted; if TLC b/w 60 and 70% predicted, high resolution computed tomography must be available to exclude significant interstitial lung disease.~5. FEV1 / FVC \< 70% predicted and FEV1 \< 60% predicted~6. Significant left-sided heart disease (based on pre-trial Echocardiogram):~   1. Significant aortic or mitral valve disease~  2. Diastolic dysfunction ; Grade II C.LV systolic function \< 45%~   d. Pericardial constriction e. Restrictive cardiomyopathy f. Significant coronary disease with demonstrable ischemia~7. Chronic renal insufficiency defined as an estimated creatinine clearance \< 30 ml/min (by MDRD equation)~8. Current atrial arrhythmias~9. Uncontrolled systemic hypertension: SBP \> 160 mm or DBP \> 100mm~10. Severe hypotension: SBP \< 80 mmHg.~11. Pregnant or breast-feeding~12. Psychiatric, addictive, or other disorder that compromises patient's ability to provide informed consent, follow study protocol, and adhere to treatment instructions~13. Co-morbid conditions that would impair a patient's exercise performance and ability to assess WHO functional class, including but not limited to chronic low-back pain or peripheral musculoskeletal problems.~14. Contraindications for magnetic resonance imaging, including significant claustrophobia, implanted metallic objects, or others as per Appendix X).~15. Known allergy to treprostinil or tadalafil.~16. Active oral nitrate use.~17. Diabetes mellitus.~18. Planned initiation of cardiac or pulmonary rehabilitation during period of study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- tadalafil alone (Type: ACTIVE_COMPARATOR): tadalafil 40mg QD(Tadalafil 20 mg QD PO increasing to 40 mg QD as tolerated).
- tadalafil and treprostinil inhalations (Type: ACTIVE_COMPARATOR): Treprostinil inhalation QID starting at 3 breaths per inhalation \& gradually increasing to 9 breaths.Each breath provides approximately 6 mcg of treprostinil.Tadalafil 20 mg QD PO increasing to 40 mg QD as tolerated.

Based on this trial design, predict the completion outcome and termination type (if applicable).